From Abandonment To Resurrection: A Look Into Xenon’s Phase 3-Ready Drug For KCNQ2-EE

Summary: Xenon Pharmaceuticals recently announced they will proceed with a pivotal, phase 3 study for their repurposed drug, XEN496, in KCNQ2-EE The repurposing of retigabine, along with the development of other anti-epileptic drugs, represented a shift in company focus following two major trial failures in 2015 (pain) and 2017 (acne) Backed with solid clinical rationale […]
To access this post, you must purchase Prime Membership, Basic Membership or Plus Membership.

This information is protected.

%d bloggers like this: